OPNT News and Press, Opiant Pharmaceuticals Inc. From 11/12/21

Shares of Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) traded today at $29.02, eclipsing its 52-week high. So far today approximately 949,000 shares have been exchanged, as compared to an average 30-day volume of 49,000 shares. Opiant Pharmaceuticals Inc is a specialty pharmaceutical compan...

Opiant Pharmaceuticals, Inc. (OPNT) Q3 2021 Earnings Conference Call November 11, 2021 4:30 PM ET Company Participants Ben Atkins - Vice President, Communications and Investor Relations Roger Crystal - President and Chief Executive Officer Matt Ruth - Chief Commercial Officer David O'Toole - ...

Opiant Pharmaceuticals (NASDAQ:OPNT): Q3 GAAP EPS of $0.56 beats by $0.35. Revenue of $16.34M (+79.4% Y/Y) beats by $4.21M. Press Release Raises full-year 2021 revenue and cash guidance Royalty revenue from the sale of NARCAN Nasal Spray now anticipated to be approximately $38 million. Cash, ...

SANTA MONICA, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and nine months en...

Opiant Pharmaceuticals (NASDAQ:OPNT) is scheduled to announce Q3 earnings results on Thursday, November 11th, after market close. The consensus EPS Estimate is $0.21 (+40.0% Y/Y) and the consensus Revenue Estimate is $12.13M (+33.2% Y/Y). Over the last 3 months, EPS estimates have seen 1 upwa...

SANTA MONICA, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT), a company advancing medicines to better treat addictions and drug overdose, today announced that members of the company’s senior management team will par...

The U.S. FDA has granted fast track designation to Opiant Pharmaceuticals' (NASDAQ:OPNT) OPNT003, nasal nalmefene, its investigational treatment for opioid overdose. Fast Track is an FDA process designed to facilitate the development and expedite the review of potential therapies that se...

Fast Track Designation further underscores the potential for OPNT003 to represent a major advance in the treatment of opioid overdose as opioid overdose deaths surge 1 This designation enables early and frequent communication with the FDA, in addition to the potentia...

SANTA MONICA, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a company advancing medicines to better treat addictions and drug overdose, today announced the publication of a manuscript entitled “ Treatment of Overdo...

SANTA MONICA, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report third quarter 2021 financial resul...